Prostate Cancer - Results from #1240

Implementation of PSMA PET/CT and alignment of ordering to SNMMI appropriate use criteria in a large network system. March 13, 2024

Prediagnostic Prostate-specific Antigen Testing and Clinical Characteristics in Men with Lethal Prostate Cancer. March 13, 2024

Dietary interventions in cancer: a systematic review of all randomized controlled trials. March 13, 2024

Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH. March 12, 2024

Major Complications and Adverse Events Related to Use of SpaceOAR Hydrogel for Prostate Cancer Radiotherapy. March 12, 2024

Mortality reduction and cumulative excess incidence (CEI) in the prostate-specific antigen (PSA) screening era. March 12, 2024

Canonical AREs are tumor suppressive regulatory elements in the prostate. March 12, 2024

Olaparib Combined with Abiraterone versus Olaparib Monotherapy for Patients with Metastatic Castration-resistant Prostate Cancer Progressing after Abiraterone and Harboring DNA Damage Repair Deficiency: A Multicenter Real-world Study. March 12, 2024

TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing. March 11, 2024

Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. March 11, 2024

Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study. March 11, 2024

Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T. March 11, 2024

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). March 11, 2024

Radical Prostatectomy for Nonmetastatic Prostate Cancer in Renal Transplant Recipients: Outcomes for a Large Contemporary Cohort and a Matched Comparison to Patients Without a Transplant. March 11, 2024

Preferences for Tailored Support - Patients' and Health Care Professionals' Experiences Regarding Symptoms and Self-Management Strategies During the First Year After Curatively Intended Prostate Cancer Treatment. March 11, 2024

BioPrev-C - development and validation of a contemporary prostate cancer risk calculator. March 8, 2024

Focal high-intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study. March 8, 2024

The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients. March 8, 2024

68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. March 8, 2024

What can patient-reported experience measures tell us about the variation in patients' experience of prostate cancer care? A cross-sectional study using survey data from the National Prostate Cancer Audit in England. March 8, 2024

Page 63 of 1436